Search

Your search keyword '"Trojan, Jörg"' showing total 843 results

Search Constraints

Start Over You searched for: Author "Trojan, Jörg" Remove constraint Author: "Trojan, Jörg"
843 results on '"Trojan, Jörg"'

Search Results

1. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

5. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

8. ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial

11. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

13. Assessment of cortical reorganization and preserved function in phantom limb pain: a methodological perspective

14. Evaluating assumptions of scales for subjective assessment of thermal environments – Do laypersons perceive them the way, we researchers believe?

15. Publisher Correction: The Scales Project, a cross-national dataset on the interpretation of thermal perception scales.

16. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

17. The Scales Project, a cross-national dataset on the interpretation of thermal perception scales.

20. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

24. TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

26. Adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction – A multicenter phase I/II feasibility study (GMBH-STO-0114)

27. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

29. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

30. Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial.

32. Heterogeneity of small duct‐ and large duct‐type intrahepatic cholangiocarcinoma

33. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion

34. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

36. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion

37. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0

38. Einführung eines interdisziplinären Tumorboards führt zur Verbesserung der Behandlungsergebnisse von Cholangio- und Gallenblasenkarzinomen

42. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

43. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

44. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies

48. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

49. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Catalog

Books, media, physical & digital resources